Vimarsana
Biggest News Aggregation in the World

Page 2 - Open Orphan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Orphan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Orphan Today - Breaking & Trending Today

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from Proposed Appointment of Non-Executive Director

Cathal Friel steps into the executive chair role at Poolbeg Pharma as leadership team beefed up - Vimarsana News

Cathal Friel steps into the executive chair role at Poolbeg Pharma as leadership team beefed up

Businessman Cathal Friel has become executive chairman of Poolbeg Pharma, the same job he had at Open Orphan (now hVivo) as that firm was developed.

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP - Vimarsana News

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP

LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board ro...

Poolbeg Pharma's Cathal Friel assumes role of Executive Chairman - Vimarsana News

Poolbeg Pharma's Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma (LON:POLB, OTCQB: POLBF) announces a change in Board role and the approval of an Employee Performance Incentive Plan to align objectives and encourage retention. Cathal Friel becomes Executive Chairman, bringing valuable experience from his successful track record in public companies. The plan aims to reward and retain key senior management for sustainable growth.

Pharmaceutical services company Hvivo sells almost 30 million placing shares - Vimarsana News

Pharmaceutical services company Hvivo sells almost 30 million placing shares

New and existing institutional investors indicated demand for shares was in excess of those available